

James W Antoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10895162/publications.pdf>

Version: 2024-02-01

36
papers

1,102
citations

361045

20
h-index

395343

33
g-index

37
all docs

37
docs citations

37
times ranked

1473
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting NF κ B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. <i>Cancer Biology and Therapy</i> , 2011, 11, 678-689.	1.5	135
2	Antiestrogenic Effects of the Novel Sphingosine Kinase-2 Inhibitor ABC294640. <i>Endocrinology</i> , 2010, 151, 5124-5135.	1.4	105
3	Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 293-300.	1.1	101
4	Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. <i>Molecular Cancer</i> , 2010, 9, 295.	7.9	89
5	MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. <i>PLoS ONE</i> , 2013, 8, e69291.	1.1	50
6	Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. <i>Journal of Molecular Endocrinology</i> , 2011, 46, 205-216.	1.1	47
7	Preferential star strand biogenesis of pre-miR-24 targets PKC α and suppresses cell survival in MCF7 breast cancer cells. <i>Molecular Carcinogenesis</i> , 2014, 53, 38-48.	1.3	45
8	Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pediatric Dermatology</i> , 2018, 35, 182-187.	0.5	40
9	Design, Synthesis, and Biological Activity of a Family of Novel Ceramide Analogues in Chemoresistant Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5748-5752.	2.9	37
10	Neurocognitive Effects of Chemotherapy and Endocrine Therapies in the Treatment of Breast Cancer: Recent Perspectives. <i>Cancer Investigation</i> , 2012, 30, 135-148.	0.6	33
11	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. <i>Scientific Reports</i> , 2012, 2, 539.	1.6	32
12	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. <i>International Journal of Oncology</i> , 2013, 42, 1139-1150.	1.4	32
13	Synthesis of 2,2'-bipyridyl-type compounds via the suzuki-miyaura cross-coupling reaction. <i>Journal of Heterocyclic Chemistry</i> , 2007, 44, 363-367.	1.4	31
14	Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1005-1007.	1.4	27
15	Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1191-1195.	1.1	26
16	Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. <i>Cancer Biology and Therapy</i> , 2012, 13, 1026-1033.	1.5	26
17	Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. <i>Experimental Biology and Medicine</i> , 2012, 237, 832-844.	1.1	25
18	Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. <i>Pharmacological Reports</i> , 2014, 66, 174-178.	1.5	24

#	ARTICLE	IF	CITATIONS
19	Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 186-193.	1.2	22
20	Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System. <i>Experimental Biology and Medicine</i> , 2009, 234, 1253-1263.	1.1	21
21	Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. <i>Oncology Reports</i> , 2012, 27, 1779-86.	1.2	20
22	A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 244-250.e1.	2.0	19
23	Sphingosine kinase: A promising cancer therapeutic target. <i>Cancer Biology and Therapy</i> , 2011, 11, 647-650.	1.5	16
24	Novel anti-viability ceramide analogs: Design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5316-5322.	1.4	15
25	Pediatric Fever of Unknown Origin. <i>Pediatrics in Review</i> , 2015, 36, 380-391.	0.2	14
26	3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1412-1420.	1.4	13
27	Clinical approach to endogenous lipoid pneumonia. <i>Clinical Respiratory Journal</i> , 2016, 10, 259-263.	0.6	13
28	Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. <i>American Journal of Cancer Research</i> , 2012, 2, 446-58.	1.4	13
29	Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamide in chemoresistant cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2624-2628.	1.0	12
30	Diagnostic Approach to Fever of Unknown Origin. <i>Clinical Pediatrics</i> , 2012, 51, 1091-1094.	0.4	7
31	Fever of Unknown Origin in a Child. <i>Clinical Pediatrics</i> , 2013, 52, 99-102.	0.4	6
32	An unusual case of pediatric shortness of breath-answers. <i>Pediatric Nephrology</i> , 2012, 27, 923-925.	0.9	3
33	An unusual case of pediatric shortness of breath-questions. <i>Pediatric Nephrology</i> , 2012, 27, 921-922.	0.9	2
34	Incomplete Reporting in a Case Report of Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis. <i>Mayo Clinic Proceedings</i> , 2012, 87, 803.	1.4	1
35	Migratory Polyarthritits in a Child. <i>Clinical Pediatrics</i> , 2012, 51, 401-403.	0.4	0
36	Severe cutaneous adverse reactions: comparing outcomes in children with and without complex chronic conditions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 790-792.e3.	2.0	0